ARDELYX, INC.
Close on Oct 19, 2026
- Market cap
- $766.53M
- P/E (TTM)
- –
- Dividend yield
- –
About Ardelyx
Pharmaceutical Preparations, SIC 2834
Ardelyx is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes small molecule therapies for unmet medical needs. It markets two products based on the active ingredient tenapanor: IBSRELA, which treats adults with irritable bowel syndrome with constipation, and XPHOZAH, which reduces serum phosphorus in adults with chronic kidney disease on dialysis. The company also develops pipeline candidates, including next-generation NHE3 inhibitors. Its end customers are adult gastrointestinal and kidney disease patients, reached through healthcare prescribers and commercial partners.
The company operates commercially in the United States through specialized sales forces and engages third-party contract manufacturers for drug production. Internationally, it establishes commercial and licensing partnerships across Canada, Japan, and China. The text does not disclose the location of the company's headquarters.
Summary of the business section of Ardelyx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ARDELYX, INC.
- Founded
- 2007
- Headquarters
- Fremont, CA
- Address
- 34175 Ardenwood Blvd. 94555
- Phone
- (510) 745-7047
- Website
- www.ardelyx.com
- Employees
- 489, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- ARDX
- Exchange
- Nasdaq
- IPO date
- Jun 19, 2014
- Shares outstanding
- 249M, Jul 30, 2026
- Public float
- $923.71M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1437402
- CUSIP
- 039697107
- ISIN
- US0396971071
- LEI
- 549300F542QR4SXHCY32
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Raab | President & CEO, Director | 1,639,970 |
| Eric Duane Foster | Chief Commercial Officer | 409,410 |
| John E. Bishop | See Remarks | 317,095 |
| Susan Hohenleitner | Chief Financial Officer | 227,520 |
| Mike Kelliher | Chief Business Officer | 351,662 |
| Joseph James Reilly | See Remarks | 146,964 |
| James Parker Brady | Chief Human Resources Officer | 259,090 |
| Laura A. Williams | Chief Patient Officer | 371,620 |
| Felecia Ettenberg | Chief Legal Officer | 237,000 |
| Rajani Dinavahi | Chief Medical Officer | 201,000 |
| Elizabeth A. Grammer | See Remarks | 302,866 |
| Edward R. Conner | Chief Medical Officer | 302,260 |
| Justin A. Renz | Chief Financial Officer | 409,052 |
| Robert Blanks | See Remarks | 314,421 |
| David P. Rosenbaum | Chief Development Officer | 525,970 |
| Merdad Parsey | Director | 83,746 |
| Onaiza Cadoret-Manier | Director | 178,156 |
| David M. Mott | Director | 9,887,572 |
| Richard J. Rodgers | Director | 439,998 |
| Muna Bhanji | Director | 163,808 |
| William C. Bertrand JR | Director | 303,052 |
| Robert B. Bazemore | Director | 68,006 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Michael Raab | $7.80M | $8.32M | $3.09M | $90 | $81 |
| FY2024 Michael Raab | $9.61M | $4.75M | $2.94M | $78 | $81 |
| FY2023 Michael Raab | $4.11M | $10.06M | $1.63M | $96 | $80 |
| FY2022 Michael Raab | $1.95M | $4.05M | $1.05M | $44 | $78 |
| FY2021 Michael Raab | $4.23M | $39.20K | $1.70M | $17 | $71 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“At December 31, 2025, we had 489 full-time employees, 93 of whom were engaged directly in research, development and manufacturing, 305 in sales and marketing and 91 in general and administrative activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 27, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 19, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 9, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jun 9, 2008 | Name change | Name changed from NTERYX INC to ARDELYX, INC. |